Who Paid My Doc
Lamzede
Drug Ert For Alpha-Mannosidosis
NDC 10122-180-02
General payments
$360,457
Research payments
$22,075
Through program year 2025, $360,457 in general payments and $22,075 in research payments were reported against Lamzede (Ert For Alpha-Mannosidosis).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $68,501 | 49 |
| 2024 | General | $72,080 | 85 |
| 2024 | Research | $22,075 | 1 |
| 2023 | General | $219,876 | 54 |
Breakdown
The top 5 of 30 recipients; each share is of general payments naming this product in 2025.
The top 5 of 9 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 16 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
188 general · 1 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.